These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9740139)

  • 1. Glycoprotein IIb-IIIa in platelet aggregation: an emerging target for the prevention of acute coronary thrombotic occlusions.
    Phillips DR; Law D; Scarborough RM
    Arch Pathol Lab Med; 1998 Sep; 122(9):811-2. PubMed ID: 9740139
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antithrombocytic effectiveness of magnesium].
    Gawaz M
    Fortschr Med; 1996 Sep; 114(26):329-32. PubMed ID: 8999005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [GP IIb/IIIa receptor antagonists--molecular and clinical aspects].
    Francuz T
    Postepy Hig Med Dosw; 2001; 55(3):419-32. PubMed ID: 11505641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
    Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
    Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
    Maree A; Fitzgerald D
    Haematologica; 2001 Nov; 86(11 Suppl 2):45-8. PubMed ID: 11926777
    [No Abstract]   [Full Text] [Related]  

  • 6. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
    Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
    Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
    Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
    Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
    Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrating GP IIb/IIIa inhibition into treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE; Roe MT
    J Invasive Cardiol; 2002 Sep; 14(9):565-74. PubMed ID: 12205361
    [No Abstract]   [Full Text] [Related]  

  • 10. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of platelets and platelet glycoprotein IIb/IIIa receptor inhibition in acute coronary syndromes: an educational supplement. Introduction.
    Joseph A
    J Emerg Med; 1999; 17(3):565. PubMed ID: 10338257
    [No Abstract]   [Full Text] [Related]  

  • 12. Simultaneous integrin alphavbeta3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty.
    Sakuma T; Sari I; Goodman CN; Lindner JR; Klibanov AL; Kaul S
    Cardiovasc Res; 2005 Jun; 66(3):552-61. PubMed ID: 15914120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet aggregation inhibitors in prevention and treatment of coronary thrombosis.
    Gomes ME; Verheugt FW
    Neth J Med; 2003 Jun; 61(6):185-92. PubMed ID: 12948162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease.
    Lefkovits J; Topol EJ
    Eur Heart J; 1996 Jan; 17(1):9-18. PubMed ID: 8682137
    [No Abstract]   [Full Text] [Related]  

  • 15. [Platelet activation and inhibition. Old and new platelet antiaggregants].
    López Bescós L; Jiménez Nacher JJ
    Rev Esp Cardiol; 1999; 52 Suppl 1():67-75. PubMed ID: 10364816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IIb/IIIa inhibitors in acute myocardial infarction.
    Montalescot G
    Blood Coagul Fibrinolysis; 1999 Feb; 10 Suppl 1():S71-5. PubMed ID: 10070824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
    Wang WY; Wu YC; Wu CC
    Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GP IIb/IIIa blockade during peripheral artery interventions.
    Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
    Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now?
    Maree A; Fitzgerald DJ
    Semin Vasc Med; 2003 Nov; 3(4):385-90. PubMed ID: 15199445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.